StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) income statement

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$4.96−0.04 (-0.80%)

Close on Nov 17, 2026Market cap $193.13MP/E –Yield –

Entrada Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-3767.1%
Net margin
-3537.7%
Return on equity, FY2025
-39.1%

Financial strength

Current ratio
10.89
Debt to equity
–
Debt to assets
–
Cash to current liabilities
464.6%

Valuation

P/E ratio
–
Price to sales
41.21
Price to book
0.83
Dividend yield
–

See a number that looks wrong?